Reference
Reference information:
http://www.ahjonline.com/article/S0002-8703(09)00772-8/abstr...
BOOKMARK ARTICLE
Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
Gregory G. Schwartz, MD, PhDaCorresponding Author Informationemail address, Anders G. Olsson, MD, PhDb, Christie M. Ballantyne, MDc, Phillip J. Barter, MD, PhDd, Ingar M. Holme, PhDe, David Kallend, MB, BSf, Lawrence A. Leiter, MDg, Eran Leitersdorf, MDh, John J.V. McMurray, MDi, Prediman K. Shah, MDj, Jean-Claude Tardif, MDk, Bernard R. Chaitman, MDl, Regina Duttlinger-Maddux, PhDf, John Mathieson, PhDf, on behalf of the dal-OUTCOMES Committees and Investigators
Received 24 July 2009; accepted 22 September 2009.
Background
Despite contemporary therapies for acute coronary syndrome (ACS), morbidity and mortality remain high. Low levels of high-density lipoprotein (HDL) cholesterol are common among patients with ACS and may contribute to ongoing risk. Strategies that raise levels of HDL cholesterol, such as inhibition of cholesterol ester transfer protein (CETP), might reduce risk after ACS. Dal-OUTCOMES is a multicenter, randomized, double-blind, placebo-controlled trial designed to test the hypothesis that CETP inhibition with dalcetrapib reduces cardiovascular morbidity and mortality in patients with recent ACS.
--------------------------------------------------
Note added at 2 hrs (2011-01-19 13:18:23 GMT)
--------------------------------------------------
so from my understanding
Dal is a reference to dalcetrapib
dalcetrapib () UKMi New Drugs Online Database
7 Sep 2010 ... The dal-OUTCOMES morbidity and mortality study in 15600 patients, which aims to evaluate dalcetrapib's effect in the reduction of ...
www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?...48... - Cached
--------------------------------------------------
Note added at 2 hrs (2011-01-19 13:18:52 GMT)
--------------------------------------------------
#
Roche - Roche announces start of new atherosclerosis study (dal ...
18 Nov 2009 ... Based on the current safety and efficacy profile of dalcetrapib, Roche announced a new Phase III clinical trial, dal-PLAQUE 2. ...
www.roche.com/investors/ir.../inv-update-2009-11-18b.htm - Cached - Similar
#
Rationale and design of dal-VESSEL: a study to assess the safety ...
by JJ Kastelein - 2010
6 Dec 2010 ... As part of the dalcetrapib dal-HEART clinical trial programme, the efficacy and safety of dalcetrapib is assessed in coronary heart disease ...
www.ncbi.nlm.nih.gov/pubmed/21128879
--------------------------------------------------
Note added at 2 hrs (2011-01-19 13:20:48 GMT)
--------------------------------------------------
http://webcache.googleusercontent.com/search?q=cache:l5Lvtrk...
Jean-Claude Tardif, direttore del centro di ricerca al Montreal Heart Institute e responsabile dello studio dal-PLAQUE 2 ha affermato che il trial ha come principale obiettivo quello di dimostrare i benefici di dalcetrapib sulla patologia aterosclerotica per un periodo superiore ai 24 mesi. Ha inoltre dichiarato che si tratta dell'unico studio che permetterà di monitorare sia la carotide sia le arterie coronarie mediante l'impiego delle tecniche di IMT e IVUS.
Inoltre, Roche ha reso noto che è a buon punto l'arruolamento dello studio dal-OUTCOMES: dei 15.600 pazienti previsti ne sono già stati arruolati 9mila. Lo studio ha l'obiettivo di verificare la capacità di dalcetrapib di ridurre i livelli di colesterolo ben al di sopra degli standard attuali.
Dalcetrapib è un nuovo anticolesterolo inibitore del CEPT, l'enzima che favorisce il trasferimento degli esteri di colesterolo dalle HDL antiaterogene alle lipoproteine contenenti l'apolipoproteina B (apoB), comprese le vLDL, le vLDL-remnants e le LDL.
È stato dimostrato che un deficit di CEPT si associa con un aumento del colesterolo HDL e una riduzione del colesterolo LDL, un profilo decisamente antiaterogeno.
| liz askew
United Kingdom
Specializes in field
Native speaker of:  English
PRO pts in category: 62
|
|
peer agreement (net): +4